ArrayExpress Uploader03714MCF-7/LTEDethanolMCF-7/LTEDethanolMCF-7/LTEDethanolMCF-7/LTEDfulvestrantMCF-7/LTEDfulvestrantMCF-7/LTEDfulvestrantHCC-1428/LTEDethanolHCC-1428/LTEDethanolHCC-1428/LTEDethanolHCC-1428/LTEDfulvestrantHCC-1428/LTEDfulvestrantHCC-1428/LTEDfulvestrantarrayexpress_sid4A significant fraction of breast cancers exhibit de novo or acquired resistance to estrogen deprivation. To model resistance to aromatase...22049316E-GEOD-22533/profile/8773/arrayexpressuploader212breastestrogenhcchormoneDec.12, 2014Falsetranscription-profiling-by-array-of-human-breast-6E-GEOD-22533_A-AFFY-44Transcription profiling by array of human breast cancer cell lines treated with fulvestrantSep.15, 2014A significant fraction of breast cancers exhibit de novo or acquired resistance to estrogen deprivation. To model resistance to aromatase inhibitor (AI) therapy, long-term estrogen-deprived (LTED) derivatives of MCF-7 and HCC-1428 cells were generated through culture for 3 and 7 months under hormone-depleted conditions, respectively. These LTED cells showed sensitivity to the ER downregulator fulvestrant under hormone-depleted conditions, suggesting continued dependence upon ER signaling for hormone-independent growth. To evaluate the role of ER in hormone-independent growth, LTED cells were treated +/- 1 uM fulvestrant x 48 h before RNA was harvested for gene expression analysis. MCF-7/LTED and HCC-1428/LTED cells were treated with 10% DCC-FBS with or without the estrogen receptor antagonist drug fulvestrant for 48 hrs prior to RNA harvest for array analysis. Three replicates per condition.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22533humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22533/samples/